CEO's greetings:
In 2013, our founding team returned from the United States to China, our motherland, founded Hangzhou DAC Biotechnology, which took root on the beautiful banks of the West Lake and the Qianjiang River.
Before returning to China, our team was engaged in antibody-drug conjugates (ADC) research and development, targeting late-stage cancers, in the US for many years. We have experienced many product failures and learned valuable experience and lessons. Since the establishment of DAC Biotechnology, we have made up our mind to make every effort to develop new ADCs with high efficacy, low toxicity and large therapeutic windows."Let original medicines benefit the world" is our mission，and the Polaris that guide us on the long pioneers’ road full of challenges. . In the past eight years, we have established a multi-functional ADC innovation and manufacture platform based on our patented novel technologies. Currently, we have 17 ADC R&D pipelines, of which three drugs are in clinical trials.
The unique ADC innovation platform that we have is strongly supported by our independent intellectual property rights, which cover about 50 kinds of intelligent linkers, five categories, a total of about 100 kinds of anti-tumor cytotoxic molecules, and 27 PCT innovation patents in the world. The total of invention patents we applied all over the world has exceeded 300, and 21 patents have been granted in the US alone. In the next few years, Hangzhou DAC Technology is expected to harvest more innovative anti-cancer drugs from our ADC platform. We have the confidence and ability in advancing more products into clinical trials in China and aboard.
Thanks to the Government and our shareholders for their constant help, thanks to all of our colleagues for their efforts and dedication, and thanks to our partners for their support. We will continue to plough deeply in the ADC's innovation field , and steadily promote clinical research. We believe that the advantages ofbest-in-class and first-in-class ADC drugs developed by Hangzhou DAC Biotechnology will be validated in clinics and gradually approaching the goal of commercialization, thus providing new treatments for patients with advanced cancers, especially advanced solid tumors.
Let our original medicine bring health to the patients and benefit the world!
